Mycenax Biotech (4726) — Strategic Asset Allocation Index
Mycenax Biotech (4726) has a Strategic Asset Allocation Index of 69.9% as of June 2023. Strategic assets (PP&E of NT$1.90 Billion plus long-term investments of NT$-) total NT$1.90 Billion, measured against net assets of NT$2.72 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Mycenax Biotech Strategic Asset Allocation Index (2017–2022)
This chart shows how Mycenax Biotech's Strategic Asset Allocation Index has evolved across 6 annual periods from 2017 to 2022. As of June 2023, the index stands at 69.9%, representing strategic assets of NT$1.90 Billion against net assets of NT$2.72 Billion TWD. Explore Mycenax Biotech cash conversion from operations to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Mycenax Biotech (2017–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Mycenax Biotech from 2017 to 2022, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Mycenax Biotech (4726) total market value.
| Year | SAAI | Strategic Assets (TWD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 63.7% | NT$1.98 Billion | NT$1.98 Billion | NT$- | NT$3.11 Billion | ▼ -7.1 pp |
| 2021 | 70.8% | NT$1.35 Billion | NT$1.35 Billion | NT$- | NT$1.91 Billion | ▲ +5.9 pp |
| 2020 | 64.9% | NT$786.73 Million | NT$786.73 Million | NT$- | NT$1.21 Billion | ▲ +11.1 pp |
| 2019 | 53.8% | NT$592.84 Million | NT$592.84 Million | NT$- | NT$1.10 Billion | ▲ +7.0 pp |
| 2018 | 46.8% | NT$424.89 Million | NT$424.89 Million | NT$- | NT$907.01 Million | ▲ +15.0 pp |
| 2017 | 31.8% | NT$363.83 Million | NT$363.83 Million | NT$- | NT$1.14 Billion | — |